Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases

Phillip A Bonney; Joshua A Santucci; Adrian J Maurer; Michael E Sughrue; Rene Y McNall-Knapp; James D Battiste

doi:10.1016/j.jocn.2015.10.022

Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases

J Clin Neurosci. 2016 Apr:26:161-3. doi: 10.1016/j.jocn.2015.10.022. Epub 2016 Jan 14.

Authors

Phillip A Bonney¹, Joshua A Santucci¹, Adrian J Maurer¹, Michael E Sughrue², Rene Y McNall-Knapp³, James D Battiste⁴

Affiliations

¹ Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
² Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Oklahoma Comprehensive Brain Tumor Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
³ Department of Pediatrics, Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
⁴ Department of Neurology, University of Oklahoma Health Sciences Center, Williams Pavilion, 920 Stanton L. Young Boulevard, Suite 2040, Oklahoma City, OK 73104, USA; Oklahoma Comprehensive Brain Tumor Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: james-battiste@ouhsc.edu.

PMID: 26777082
DOI: 10.1016/j.jocn.2015.10.022

Abstract

There is little evidence to guide the choice of chemotherapeutic agents for osseous metastases in medulloblastoma. Recently, triple therapy with temozolomide, irinotecan, and bevacizumab has been reported to have efficacy in recurrent medulloblastoma, and this regimen alone and in combination with other agents has been tested in several early-phase clinical trials. Here we report a 20-year-old woman with multiply-relapsed medulloblastoma with numerous osseous metastases 8 years after original diagnosis who responded dramatically to temozolomide, irinotecan, and bevacizumab therapy. This case highlights the potential for this regimen in treating osseous metastases in medulloblastoma.

Keywords: Bevacizumab; Irinotecan; Medulloblastoma; Osseous metastasis; Recurrent; Temozolomide.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / administration & dosage
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Cerebellar Neoplasms / drug therapy*
Cerebellar Neoplasms / pathology
Dacarbazine / administration & dosage
Dacarbazine / analogs & derivatives
Female
Humans
Irinotecan
Medulloblastoma / drug therapy*
Medulloblastoma / secondary
Temozolomide
Young Adult

Substances

Bevacizumab
Irinotecan
Dacarbazine
Camptothecin
Temozolomide